**Name of Journal:** *World Journal of Hepatology*

**Manuscript NO.:** 75981

**Manuscript Type:** ORIGINAL ARTICLE

***Observational Study***

**Pre-sarcopenia and Mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinoma**

Nakai M *et al*. Prediction of HCC by M2BPGi and pre-sarcopenia

Masato Nakai, Kenichi Morikawa, Shunichi Hosoda, Sonoe Yoshida, Akinori Kubo, Yoshimasa Tokuchi, Takashi Kitagataya, Ren Yamada, Masatsugu Ohara, Takuya Sho, Goki Suda, Koji Ogawa, Naoya Sakamoto

**Masato Nakai, Kenichi Morikawa, Shunichi Hosoda, Sonoe Yoshida, Akinori Kubo, Yoshimasa Tokuchi, Takashi Kitagataya, Ren Yamada, Masatsugu Ohara, Takuya Sho, Goki Suda, Koji Ogawa, Naoya Sakamoto,** Department of Gastroenterology and Hepatology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, Sapporo 060-8638, Japan

**Author contributions:** Nakai M and Morikawa K planned the contents of manuscript; Nakai M, Morikawa K, Hosoda S, Yoshida S, Kubo A, Tokuchi Y, Kitagataya T, Yamada R, Ohara M, Sho T, Suda G, Ogawa K, and Sakamoto N collected the data; Nakai M and Morikawa K analyzed the data and drafted the manuscript; all authors revised the manuscript.

**Corresponding author: Kenichi Morikawa, MD, PhD, Associate Professor,** Department of Gastroenterology and Hepatology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, Kita 15 Nishi 7, Kita-ku, Sapporo 0608638, Hokkaido, Japan. kenichi.morikawa@med.hokudai.ac.jp

**Received:** February 25, 2022

**Revised:** April 20, 2022

**Accepted: June 22, 2022**

**Published online:**

**Abstract**

BACKGROUND

The Mac-2 binding protein glycosylation isomer (M2BPGi), a fibrosis marker in various liver diseases, is reportedly a prognostic marker in patients with hepatocellular carcinoma (HCC) who underwent hepatectomy.

AIM

To evaluate whether the M2BPGi value, M2BP, and pre-sarcopenia before radiofrequency ablation (RFA) could be useful recurrence and prognostic markers in patients with early-stage HCC.

METHODS

In total, 160 patients with early-stage primary HCC treated with RFA were separately analyzed as hepatitis C virus (HCV)-positive and HCV-negative. Factors contributing to recurrence and liver-related death, including M2BP, M2BPGi, and skeletal muscle mass index, were statistically analyzed. Eighty-three patients were HCV-positive and 77 were HCV-negative.

RESULTS

In HCV-positive patients, only des-γ-carboxy-prothrombin ≥ 23 mAU/mL was a significant poor prognostic factor affecting survival after RFA. In HCV-negative patients, M2BPGi ≥ 1.86 cutoff index was significantly associated with tumor recurrence, while M2BP was not. M2BPGi ≥ 1.86 cutoff index (hazard ratio, 4.89; 95% confidence interval: 1.97-12.18; *P <* 0.001) and pre-sarcopenia (hazard ratio, 3.34, 95% confidence interval: 1.19-9.37; *P* = 0.022) were independent significant poor prognostic factors in HCV-negative patients.

CONCLUSION

In HCV-negative patients with primary HCC treated with RFA, lower M2BPGi contributed to a lower tumor recurrence rate and longer survival period. Pre-sarcopenia contributed to the poor prognosis independently in HCV-negative patients. These factors might be useful recurrence and prognostic markers for early-stage primary HCC.

**Keywords:** Mac-2 binding protein; Mac-2 binding protein glycosylation isomer; Pre-sarcopenia; Primary hepatocellular carcinoma; Radiofrequency ablation

Nakai M, Morikawa K, Hosoda S, Yoshida S, Kubo A, Tokuchi Y, Kitagataya T, Yamada R, Ohara M, Sho T, Suda G, Ogawa K, Sakamoto N. Pre-sarcopenia and Mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinoma. *World J Hepatol* 2022; In press

**Core Tip:** Hepatocellular carcinoma (HCC) is prone to recurrence, even if cured at an early stage. Pre-sarcopenia is a poor prognostic factor in the elderly population. The usefulness of the Mac-2 binding protein glycosylation isomer (M2BPGi) to treat HCC has recently attracted attention. In this study, we investigated the recurrence and prognostic factors in patients who underwent radiofrequency ablation for early-stage HCC. Based on our data, pre-sarcopenia and higher M2BPGi, but not M2BP, were useful predictors of the recurrence and poor prognosis of early-stage primary HCC in hepatitis C virus-negative patients.

**INTRODUCTION**

Hepatocellular carcinoma (HCC) is an important health problem affecting approximately 900,000 new cancer cases worldwide. In 2020, > 800,000 people died from HCC, accounting for approximately 8.3% of cancer deaths[1]. HCC often results from cirrhosis or chronic liver injury caused by background diseases, such as hepatitis C virus (HCV), hepatitis B virus (HBV), primary biliary cholangitis (PBC), autoimmune hepatitis (AIH), alcoholic liver disease, and nonalcoholic steatohepatitis (NASH). In the last 25 years, treatment for viral hepatitis has made great strides. Notably, HCV can be eliminated in almost all cases using direct-acting antivirals (DAAs). Although HBV is still an important risk factor that accounts for approximately 50% of the causes of HCC, the proportion of non-viral liver diseases, especially steatohepatitis, as the causative disease of HCC is increasing[2].

HCC is prone to recurrence, even if cured at an early stage. In the Barcelona Clinic Liver Cancer (BCLC) staging system[3-5], which is widely used in the treatment of HCC, early-stage HCC is classified as stage 0 or A. BCLC stage 0 is defined as very early stage, for single nodule ≤ 2 cm, Child-Pugh A, Eastern Cooperative Oncology Group Performance status (PS) 0. BCLC stage A is defined as the early stage and is the case of maximum tumor diameter ≤ 3 cm, number of tumors ≤ 3, Child-Pugh A-B, and PS 0. Liver transplantation is considered in some unresectable cases of stage A disease, but resection and ablation are often recommended as curative treatments. In recent years, a median overall survival > 6 years has been expected for early-stage liver cancer patients undergoing BCLC-0 of A liver resection and ablation[6]. However, even in the case of liver resection for early-stage HCC, the prognosis is poor in cases of portal hypertension[7,8].

Radiofrequency ablation (RFA) is the most widely used local therapy for HCC treatment. It has been reported that the 4-year local recurrence rate after RFA in the early stage is approximately 5%-10% and the 5-year survival rate is approximately 70%[9-13]. However, it has been reported that cases with impaired liver function and/or bad tumor conditions (large tumor diameter and large number of tumors) have a poor prognosis[13].

In recent years, many studies have demonstrated that sarcopenia is a poor prognostic factor in patients with chronic liver disease and HCC, because it is related to frailty, loss of function, and low quality of life. Sarcopenia is diagnosed using both muscle power loss and muscle volume loss according to the Japan Society of Hepatology (JSH) diagnostic guidelinesor European diagnostic guidelines[14-16]. Pre-sarcopenia is defined as muscle volume loss without muscle power loss, and has been reported to be a poor prognostic factor in the elderly population[17].

In addition, the usefulness of the Mac-2 binding protein glycosylation isomer (M2BPGi), or Wisteria floribunda agglutinin (WFA)-positive M2BP, which was first reported as a fibrosis marker in HCV patients, to treat HCC has recently attracted attention[18]. M2BPGi is a serum marker predicting fibrosis in HCV and other liver diseases, such as HBV, AIH, PBC, and NASH[19-22]. It is also a useful predictor of HCC in various liver diseases[23-27].

In this study, we investigated the usefulness of pre-sarcopenia, M2BPGi, and M2BP as recurrence and prognostic factors in patients who underwent RFA for early-stage HCC.

**MATERIALS AND METHODS**

***Patients and data collection***

A total of 202 patients underwent RFA for primary HCC between 2001 and 2017 at Hokkaido University Hospital, 160 of whom were diagnosed with BCLC stage 0 or A and followed up > 6 mo after RFA. Patients with HCV-RNA positive were classified to “HCV-positive” group and HCV-RNA negative were classified to “HCV-negative” group. Blood chemistry data, tumor factors (tumor number, size, and form), and clinical symptoms including ascites, pleural effusion, and hepatic encephalopathy were obtained before RFA.

***Percutaneous RFA procedure***

Percutaneous RFA was performed using a cooled-tip electrode (Cool-Tip; Ablation Systems, Covidien, Boulder, Colombia, CO) after ultrasonography (US) planning. RFA was performed by experienced operators under real-time ultrasound guidance. In some cases, we used a contrast-enhanced US technique or a real-time visual support system to detect the tumor more clearly. Moreover, in some cases, artificial ascites or pleural fluid can prevent thermal injury to extrahepatic organs or avoid the lungs in the tracking line. The ablation time, including three occurrences of roll-off, was 3-12 min. The ablated lesion and ablative margin were assessed using dynamic computed tomography (CT) or magnetic resonance imaging (MRI) 1-4 d after RFA.

***Follow up and definition of recurrence of HCC***

Because of the early detection of local and distant recurrence, the first imaging test (dynamic CT or MRI) after RFA was performed 4-8 wk after RFA. After the initial evaluation, follow-up by imaging (dynamic CT or MRI) and serum tumor markers such as alpha-fetoprotein (AFP), lens culinaris agglutinin-A reactive AFP isoform (AFP-L3), and des-γ-carboxy-prothrombin (DCP) were performed every 3-4 mo. Chest CT was regularly performed to detect distant metastases.

***The treatment for recurrence and the definition of deaths***

For HCC recurrence, appropriate treatment was performed according to liver cancer treatment guidelines[28-31]. Deaths due to liver cancer, liver failure (including acute or chronic liver failure), hemorrhage due to gastroesophageal varices, and infections associated with spontaneous bacterial peritonitis were defined as liver-related deaths. Deaths other than liver diseases, such as other organ cancers, ischemic heart disease, and pneumonia, were analyzed as survival sensors.

***The diagnosis of pre-sarcopenia***

Pre-sarcopenia was assessed according to the sarcopenia assessment criteria of the JSH guidelines for sarcopenia in liver disease[14]. Skeletal muscle mass index (SMI) calculated using simple methods[14,16]. In particular, the left-right sum of the long axis times the short axis of the iliopsoas muscles at the level of the third lumbar vertebra (L3) divided by height squared. This method has been reported to correlate well with SMI calculated using a muscle mass measurement software.

***Measurement of M2BPGi and M2BP***

M2BPGi levels were measured in the conserved serum before RFA and at 1 mo after RFA. M2BPGi detection was based on a lectin-antibody sandwich immunoassay (Sysmex Co., Kobe, Japan) and expressed as a cutoff index (COI), with a range of 0.1-20 COI as previously reported[18].

M2BP was measured in conserved serum using enzyme-linked immunosorbent assay methods (Human Mac-2 binding protein (Mac-2bp) Assay Kit, Immuno-Biological Laboratories Co., Ltd., Fujioka, Japan).

***Statistical analysis***

Statistical analyses were performed using EZR software[32]. The Mann-Whitney U test was used to analyze continuous variables. Fisher’s exact test was used for univariate analysis of ordered variables. The Kaplan-Meier method was used to determine recurrence and survival rates, and the log-rank test was used to analyze differences. The median value was used as the cutoff. For the multivariate analysis of factors related to recurrence and survival, Cox proportional hazards models with stepwise methods using p-values were used.

***Ethical considerations***

The study protocol was approved by the Institutional Ethics Committee of Hokkaido University (IRB-No. 015-1412) and conformed to the ethical guidelines of the Declaration of Helsinki.

**RESULTS**

***Patient characteristics***

As shown in Figure 1, 202 patients underwent RFA for primary HCCs. Of these, 160 cases were classified as BCLC stage 0 or A, and the data were analyzed. Eighty-three patients were classified into the HCV-positive group, and 77 patients were classified into the HCV-negative group. The ratio of older age and Child-Pugh Grade B was higher in the HCV-positive group than in the HCV-negative group. Serum transaminase and fibrosis-4 (FIB-4) index were higher in the HCV-positive group than in the HCV-negative group. In addition, the serum AFP and AFP-L3 levels were higher in the HCV-positive group. The median tumor diameter and number were not significantly different; however, they tended to be larger in the HCV-positive group than in the HCV-negative group. In contrast, the SMI of the HCV-positive group was significantly lower than that of the HCV-negative group (Table 1).

***M2BP and M2BPGi values in HCV-positive and -negative patients***

In the HCV-positive group, the median M2BP was 5385 ng/mL and that of M2BPGi was 4.94 COI. On the other hand, in the HCV-negative group, the median M2BP was 2745 ng/mL and that of M2BPGi was 1.86 COI. M2BP and M2BPGi levels were significantly higher in the HCV-positive group than in the negative group (Figure 2). Therefore, we used the median as the cutoff value in the following analysis for each group.

***M2BPGi, not M2BP, is the risk factor of recurrence in HCV-negative patients***

Next, we examined whether M2BP and M2BPGi could be predictive factors for HCC recurrence in primary HCC patients with BCLC stage 0 or A. M2BP could not be a predictive factor for HCC recurrence in each group, but M2BPGi could be a clinical predictor for HCC recurrence only in the HCV-negative group (Figure 3). Therefore, it is suggested that M2BPGi, but not M2BP, is a predictive factor for HCC recurrence in patients without current HCV infection.

***Higher M2BPGi levels and pre-sarcopenia are risk factors for liver-related death in HCV-negative patient*s**

For further analysis, we examined whether M2BP and M2BPGi could be predictive factors of liver-related death in BCLC stage 0 or A. In the HCV-positive group, older age (≥ 70 years), albumin-bilirubin (ALBI) grade 2 or 3, DCP ≥ 23 mAU/L, and AFP-L3 ≥ 10% were factors contributing to a negative effect on survival on univariate analysis. Only DCP ≥ 23 mAU/L was a factor contributing to a negative effect on survival on multivariate analysis, and higher M2BP and M2BPGi were not significant factors for a negative effect on survival in the HCV-positive group (Table 2). In contrast, in the HCV-negative group, M2BPGi ≥ 1.86 COI and pre-sarcopenia were significant factors contributing to a negative effect on survival (Table 3). In the HCV-negative patient group, M2BPGi, but not M2BP, was a poor prognostic factor (Figure 4). Similarly, pre-sarcopenia was a poor prognostic factor only in the HCV-negative group (Figure 5). Therefore, higher M2BPGi and pre-sarcopenia were poor prognostic factors in patients without active HCV infection.

**DISCUSSION**

In this study, we retrospectively analyzed the prognostic factors of early-stage HCC (BCLC stage 0-A) after RFA treatment. Here, we investigated the usefulness of M2BGi and M2BP as predictors of HCC recurrence and prognosis. As a result, M2BPGi and pre-sarcopenia were useful in HCC recurrence and as prognostic factors in patients without current HCV infection.

Many randomized controlled trials[11,33-40] have compared the treatment outcomes of hepatectomy and RFA for early-stage HCC, but there are few reports with high quality evidence[11,39,40]. In recent years, Ng *et al*[11] reported no statistically significant difference in recurrence-free survival between hepatectomy and RFA in 109 cases. In the SURF trial, hepatectomy and RFA for HCC with a Child-Pugh score ≤ 7, tumor diameter ≤ 3 cm, and tumor number ≤ 3 had equivalent recurrence-free survival[39]. Based on the above, RFA has almost the same therapeutic results as hepatectomy for BCLC stage 0/A HCC. Considering that RFA is less invasive than hepatectomy, it is expected to become a standard treatment.

However, it has been reported that local recurrence is observed in approximately 10% of cases in which a sufficient ablation area is obtained by RFA[41,42]. The risk factors for recurrence have also been reported. Shiina *et al* reported that, in a large number of cases, a higher DCP was associated with local recurrence. Ectopic recurrence is associated with HCV positivity, Child-Pugh grade B or C, platelet counts ≤ 100,000, higher AFP, higher DCP, large tumor diameter, and a large number of tumors[13]. Thus, regarding the recurrence of HCC after RFA, not only tumor factors but also factors related to liver function are largely involved. Contrarily, factors related to survival after RFA including younger age, lack of portosystemic shunt, Child-Pugh grade A, lower bilirubin, lower ALBI score, higher albumin, higher prothrombin time, lower AFP, HBV positivity, lower neutrophil to lymphocyte ratio, small tumor diameter, and low tumor number have been reported in a meta-analysis[43]. Therefore, liver function and pretreatment tumor factors are considered important factors not only for recurrence but also for survival.

In this study, we focused on M2BPGi and muscle mass, which are not direct tumor factors and liver function. M2BP is a secreted glycoprotein of approximately 90 kDa that was originally reported as a ligand for galectin[44]. The serum concentration of M2BP has been reported to increase in various cancers, such as breast and lung cancers[45]. Furthermore, Kamada *et al*[46] reported its usefulness as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease. M2BPGi has a sugar chain with an affinity for WFA and distinguishes the glycan structure of WFA-detectable M2BP. The usefulness of M2BPGi as a marker of liver fibrosis in patients with HCV infection was reported in 2013[18]. M2BPGi has also been reported to be useful as a fibrosis marker in various liver diseases[19-22]. However, the M2BPGi value differs depending on the background liver disease, and it has been reported that the predicted cutoff value of METAVIR scoring system in the F4 stage is 5.2 COI for HCV, 3.1 COI for HBV, and 0.91 COI for NASH[47,48]. M2BPGi is an interferon (IFN)-simulated protein, and the amount of M2BPGi decreases after HCV eradication[49]. Therefore, it is suggested that M2BPGi is high in patients currently infected with HCV, even with the same degree of liver fibrosis. In this study, the median values differed significantly between the HCV-positive and HCV-negative patients. The M2BPGi levels were significantly higher in HCV-positive patients than in HCV-negative patients (Figure 2). Therefore, we analyzed the M2BPGi values separately in HCV-positive and HCV-negative patients.

M2BPGi has also been reported as a useful marker for predicting the occurrence of HCC. Specifically, it has been reported as a marker for predicting HCC in HCV, HBV and post-HCV eradication cases[19,23,25,27,49-57]. In this study, M2BPGi significantly predicted recurrence in HCV-negative cases. In contrast, M2BP level was not be a predictor of recurrence. Progression of liver fibrosis is a risk factor for HCC. As M2BPGi reflects liver fibrosis, M2BPGi may be indirectly associated with the development of HCC. M2BPGi may show higher levels in HCV cases than in others, even at similar levels of liver fibrosis. This is because the inflammation caused by the current HCV infection might affect the M2BPGi value in the HCV-positive group. Therefore, predicting HCC recurrence may be difficult using the value of M2BPGi only in HCV-positive cases. Based on the results of this study, prediction of cases at a high risk for recurrence after RFA was possible in early-stage HCC by focusing on the value of M2BPGi in HCV-negative patients.

Furthermore, M2BPGi has been reported to be a useful marker for predicting the prognosis of patients after HCV eradication, hepatectomy,and transcatheter arterial chemoembolization[25,58,59]. In this study, we analyzed prognostic factors after RFA for early-stage HCC, focusing on M2BP, M2BPGi, and pre-sarcopenia. In HCV-positive cases, DCP that is one of the serum tumor markers of HCC was a significant poor prognosis factor. In contrast, in HCV-negative cases, M2BPGi and pre-sarcopenia were significant poor prognostic factors, but tumor factors (tumor number, size, form, and serum markers) were not. In addition, M2BP was not a prognostic predictor in either group. M2BPGi levels are affected by various factors, including acute liver failure, and are associated with liver inflammation, damage, and hepatocyte degeneration[60]. Furthermore, M2BPGi was reported to correlate with inflammatory cytokines and was reduced by steroid treatment in patients with autoimmune hepatitis[61]. In HCV-negative cases, high M2BPGi levels may indicate advanced fibrosis or coexistence of inflammation because these cases are not affected by HCV. Therefore, M2BPGi may be a predictor of liver-related death. Notably, M2BPGi was a more sensitive prognostic marker than other liver function or fibrosis markers such as ALBI and FIB-4 in HCV-negative patients. Thus, M2BPGi may be a marker that can predict poor prognosis, including the effects of other factors, such as inflammation and liver fibrosis.

Patients with chronic liver disease and sarcopenia have a significantly poorer prognosis[62]. Furthermore, it has been reported that in the elderly, pre-sarcopenia cases have a poorer prognosis than non-sarcopenia cases[17]. In this study, pre-sarcopenia was a significant poor prognostic factor in HCV-negative cases but was not a significant prognostic factor in HCV-positive cases. The reason for this might be related to the fact that HCV-positive patients had significantly less SMI than the HCV RNA-negative patient group (Table 1). Because muscle volume increases after IFN-free treatment in HCV-positive patientsand HCV elimination suppresses pre-sarcopenia, the current HCV infection itself may contribute to pre-sarcopenia. In this study, the high proportion of cases of pre-sarcopenia and the elderly may have affected the observation that pre-sarcopenia was not a significant prognostic factor in HCV-positive cases[63,64].

This study has several limitations. First, it was a retrospective observational study involving a single hospital and a small number of patients. Second, SMI was evaluated using only the simple CT method. Further studies with larger patient numbers and multicenter evaluations are needed.

**CONCLUSION**

In the near future, almost all HCVs will be eradicated by DAA treatment. Henceforth, almost no HCC cases were derived from the current HCV infection. In this study, we investigated the predictive factors of survival after RFA for HCC in BCLC stage 0 or A patients divided into two groups: HCV-RNA positive and negative. Pre-sarcopenia and M2BPGi, but not M2BP, might be useful tools for the prediction of survival in early-stage HCC in the era of HCV eradication.

**ARTICLE HIGHLIGHTS**

***Research background***

Hepatocellular carcinoma (HCC) is prone to recurrence, even if cured at an early stage. In recent years, many studies have demonstrated that sarcopenia is a poor prognostic factor in patients with chronic liver disease and HCC, because it is related to frailty, loss of function, and low quality of life. Pre-sarcopenia is defined as muscle volume loss without muscle power loss and is a poor prognostic factor in the elderly population. In addition, the usefulness of the Mac-2 binding protein glycosylation isomer (M2BPGi), or Wisteria floribunda agglutinin-positive M2BP, which was first reported as a fibrosis marker in hepatitis C virus (HCV) patients, to treat HCC has recently attracted attention.

***Research motivation***

The M2BPGi, a fibrosis marker in various liver diseases, is reportedly a prognostic marker in patients with HCC who underwent hepatectomy. In recent years, many studies have demonstrated that sarcopenia is a poor prognostic factor in patients with chronic liver disease and HCC, because it is related to frailty, loss of function, and low quality of life. Sarcopenia is diagnosed using both muscle power loss and muscle volume loss. Pre-sarcopenia is defined as muscle volume loss without muscle power loss and is a poor prognostic factor in the elderly population.

***Research objectives***

To investigate the usefulness of pre-sarcopenia, M2BPGi, and M2BP as recurrence and prognostic factors in patients who underwent RFA for early-stage HCC.

***Research methods***

In this study, 202 patients underwent radiofrequency ablation (RFA) for primary HCCs. Of these, 160 cases were classified as BCLC stage 0 or A, and the data were analyzed. Eighty-three patients were classified into the HCV-positive group, and 77 patients were classified into the HCV-negative group.

***Research results***

In HCV-positive patients, only des-γ-carboxy-prothrombin (DCP) ≥ 23 mAU/mL was a significant poor prognostic factor affecting survival after RFA. In HCV-negative patients, M2BPGi ≥ 1.86 cutoff index was significantly associated with tumor recurrence, but M2BP was not. M2BPGi ≥ 1.86 cutoff index (hazard ratio, 4.89; 95% confidence interval: 1.97-12.18; *P <* 0.001) and pre-sarcopenia (hazard ratio, 3.34, 95% confidence interval: 1.19-9.37; *P* = 0.022) were independent significant poor prognostic factors in HCV-negative patients.

***Research conclusions***

In HCV-negative patients with primary HCC treated with RFA, lower M2BPGi contributed to a lower tumor recurrence rate and longer survival period. Pre-sarcopenia contributed to the poor prognosis independently in HCV-negative patients.

***Research perspectives***

In the near future, almost all HCVs will be eradicated by DAA treatment. Almost no HCC cases were derived from the current HCV infection. Pre-sarcopenia and M2BPGi, but not M2BP, might be useful tools to predict survival in early-stage HCC in the era of HCV eradication.

**REFERENCES**

1 **International Agency for Reserach on Cancer**. Cancer fact sheets, 2020. [cited 20 April 2022]. Available from: https://gco.iarc.fr/today/fact-sheets-cancers

2 **Global Burden of Disease Liver Cancer Collaboration,** Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, Al-Raddadi R, Alvis-Guzman N, Amoako Y, Artaman A, Ayele TA, Barac A, Bensenor I, Berhane A, Bhutta Z, Castillo-Rivas J, Chitheer A, Choi JY, Cowie B, Dandona L, Dandona R, Dey S, Dicker D, Phuc H, Ekwueme DU, Zaki MS, Fischer F, Fürst T, Hancock J, Hay SI, Hotez P, Jee SH, Kasaeian A, Khader Y, Khang YH, Kumar A, Kutz M, Larson H, Lopez A, Lunevicius R, Malekzadeh R, McAlinden C, Meier T, Mendoza W, Mokdad A, Moradi-Lakeh M, Nagel G, Nguyen Q, Nguyen G, Ogbo F, Patton G, Pereira DM, Pourmalek F, Qorbani M, Radfar A, Roshandel G, Salomon JA, Sanabria J, Sartorius B, Satpathy M, Sawhney M, Sepanlou S, Shackelford K, Shore H, Sun J, Mengistu DT, Topór-Mądry R, Tran B, Ukwaja KN, Vlassov V, Vollset SE, Vos T, Wakayo T, Weiderpass E, Werdecker A, Yonemoto N, Younis M, Yu C, Zaidi Z, Zhu L, Murray CJL, Naghavi M, Fitzmaurice C. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. *JAMA Oncol* 2017; **3**: 1683-1691 [PMID: 28983565 DOI: 10.1001/jamaoncol.2017.3055]

3 **Llovet JM**, Villanueva A, Marrero JA, Schwartz M, Meyer T, Galle PR, Lencioni R, Greten TF, Kudo M, Mandrekar SJ, Zhu AX, Finn RS, Roberts LR; AASLD Panel of Experts on Trial Design in HCC. Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. *Hepatology* 2021; **73 Suppl 1**: 158-191 [PMID: 32430997 DOI: 10.1002/hep.31327]

4 **European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu.**; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. *J Hepatol* 2018; **69**: 182-236 [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019]

5 **Llovet JM**, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. *Semin Liver Dis* 1999; **19**: 329-338 [PMID: 10518312 DOI: 10.1055/s-2007-1007122]

6 **Llovet JM**, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. *Nat Rev Dis Primers* 2021; **7**: 6 [PMID: 33479224 DOI: 10.1038/s41572-020-00240-3]

7 **Ishizawa T**, Hasegawa K, Aoki T, Takahashi M, Inoue Y, Sano K, Imamura H, Sugawara Y, Kokudo N, Makuuchi M. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. *Gastroenterology* 2008; **134**: 1908-1916 [PMID: 18549877 DOI: 10.1053/j.gastro.2008.02.091]

8 **Llovet JM**, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection *vs* transplantation. *Hepatology* 1999; **30**: 1434-1440 [PMID: 10573522 DOI: 10.1002/hep.510300629]

9 **Xia Y**, Li J, Liu G, Wang K, Qian G, Lu Z, Yang T, Yan Z, Lei Z, Si A, Wan X, Zhang H, Gao C, Cheng Z, Pawlik TM, Wang H, Lau WY, Wu M, Shen F. Long-term Effects of Repeat Hepatectomy *vs* Percutaneous Radiofrequency Ablation Among Patients With Recurrent Hepatocellular Carcinoma: A Randomized Clinical Trial. *JAMA Oncol* 2020; **6**: 255-263 [PMID: 31774468 DOI: 10.1001/jamaoncol.2019.4477]

10 **Xu XL**, Liu XD, Liang M, Luo BM. Radiofrequency Ablation *vs* Hepatic Resection for Small Hepatocellular Carcinoma: Systematic Review of Randomized Controlled Trials with Meta-Analysis and Trial Sequential Analysis. *Radiology* 2018; **287**: 461-472 [PMID: 29135366 DOI: 10.1148/radiol.2017162756]

11 **Ng KKC**, Chok KSH, Chan ACY, Cheung TT, Wong TCL, Fung JYY, Yuen J, Poon RTP, Fan ST, Lo CM. Randomized clinical trial of hepatic resection *vs* radiofrequency ablation for early-stage hepatocellular carcinoma. *Br J Surg* 2017; **104**: 1775-1784 [PMID: 29091283 DOI: 10.1002/bjs.10677]

12 **Peng ZW**, Zhang YJ, Chen MS, Xu L, Liang HH, Lin XJ, Guo RP, Zhang YQ, Lau WY. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. *J Clin Oncol* 2013; **31**: 426-432 [PMID: 23269991 DOI: 10.1200/JCO.2012.42.9936]

13 **Shiina S**, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Sato T, Masuzaki R, Kondo Y, Goto T, Yoshida H, Omata M, Koike K. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. *Am J Gastroenterol* 2012; **107**: 569-577; quiz 578 [PMID: 22158026 DOI: 10.1038/ajg.2011.425]

14 **Nishikawa H**, Shiraki M, Hiramatsu A, Moriya K, Hino K, Nishiguchi S. Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria. *Hepatol Res* 2016; **46**: 951-963 [PMID: 27481650 DOI: 10.1111/hepr.12774]

15 **Cruz-Jentoft AJ**, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. *Age Ageing* 2019; **48**: 16-31 [PMID: 30312372 DOI: 10.1093/ageing/afy169]

16 **Cruz-Jentoft AJ**, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinková E, Vandewoude M, Zamboni M; European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. *Age Ageing* 2010; **39**: 412-423 [PMID: 20392703 DOI: 10.1093/ageing/afq034]

17 **Lera L**, Angel B, Marquez C, Saguez R, Albala C. Besides Sarcopenia, Pre-Sarcopenia Also Predicts All-Cause Mortality in Older Chileans. *Clin Interv Aging* 2021; **16**: 611-619 [PMID: 33883888 DOI: 10.2147/CIA.S289769]

18 **Kuno A**, Ikehara Y, Tanaka Y, Ito K, Matsuda A, Sekiya S, Hige S, Sakamoto M, Kage M, Mizokami M, Narimatsu H. A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. *Sci Rep* 2013; **3**: 1065 [PMID: 23323209 DOI: 10.1038/srep01065]

19 **Ishii A**, Nishikawa H, Enomoto H, Iwata Y, Kishino K, Shimono Y, Hasegawa K, Nakano C, Takata R, Nishimura T, Yoh K, Aizawa N, Sakai Y, Ikeda N, Takashima T, Iijima H, Nishiguchi S. Clinical implications of serum Wisteria floribunda agglutinin-positive Mac-2-binding protein in treatment-naïve chronic hepatitis B. *Hepatol Res* 2017; **47**: 204-215 [PMID: 26990490 DOI: 10.1111/hepr.12703]

20 **Nishikawa H**, Enomoto H, Iwata Y, Hasegawa K, Nakano C, Takata R, Nishimura T, Yoh K, Aizawa N, Sakai Y, Ikeda N, Takashima T, Iijima H, Nishiguchi S. Clinical significance of serum Wisteria floribunda agglutinin positive Mac-2-binding protein level and high-sensitivity C-reactive protein concentration in autoimmune hepatitis. *Hepatol Res* 2016; **46**: 613-621 [PMID: 26406984 DOI: 10.1111/hepr.12596]

21 **Umemura T**, Joshita S, Sekiguchi T, Usami Y, Shibata S, Kimura T, Komatsu M, Matsumoto A, Ota M, Tanaka E. Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein Level Predicts Liver Fibrosis and Prognosis in Primary Biliary Cirrhosis. *Am J Gastroenterol* 2015; **110**: 857-864 [PMID: 25916223 DOI: 10.1038/ajg.2015.118]

22 **Abe M**, Miyake T, Kuno A, Imai Y, Sawai Y, Hino K, Hara Y, Hige S, Sakamoto M, Yamada G, Kage M, Korenaga M, Hiasa Y, Mizokami M, Narimatsu H. Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. *J Gastroenterol* 2015; **50**: 776-784 [PMID: 25326152 DOI: 10.1007/s00535-014-1007-2]

23 **Yamasaki K**, Tateyama M, Abiru S, Komori A, Nagaoka S, Saeki A, Hashimoto S, Sasaki R, Bekki S, Kugiyama Y, Miyazoe Y, Kuno A, Korenaga M, Togayachi A, Ocho M, Mizokami M, Narimatsu H, Yatsuhashi H. Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients. *Hepatology* 2014; **60**: 1563-1570 [PMID: 25042054 DOI: 10.1002/hep.27305]

24 **Toyoda H**, Kumada T, Tada T, Kaneoka Y, Maeda A, Korenaga M, Mizokami M, Narimatsu H. Serum WFA+ -M2BP levels as a prognostic factor in patients with early hepatocellular carcinoma undergoing curative resection. *Liver Int* 2016; **36**: 293-301 [PMID: 26134114 DOI: 10.1111/Liv.12907]

25 **Nagata H**, Nakagawa M, Asahina Y, Sato A, Asano Y, Tsunoda T, Miyoshi M, Kaneko S, Otani S, Kawai-Kitahata F, Murakawa M, Nitta S, Itsui Y, Azuma S, Kakinuma S, Nouchi T, Sakai H, Tomita M, Watanabe M; Ochanomizu Liver Conference Study Group. Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. *J Hepatol* 2017; **67**: 933-939 [PMID: 28627363 DOI: 10.1016/j.jhep.2017.05.028]

26 **Kawanaka M**, Tomiyama Y, Hyogo H, Koda M, Shima T, Tobita H, Hiramatsu A, Nishino K, Okamoto T, Sato S, Hara Y, Nishina S, Kawamoto H, Chayama K, Okanoue T, Hino K. Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts the development of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. *Hepatol Res* 2018; **48**: 521-528 [PMID: 29316028 DOI: 10.1111/hepr.13054]

27 **Tseng TC**, Peng CY, Hsu YC, Su TH, Wang CC, Liu CJ, Yang HC, Yang WT, Lin CH, Yu ML, Lai HC, Tanaka Y, Nguyen MH, Liu CH, Chen PJ, Chen DS, Kao JH. Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy. *Liver Cancer* 2020; **9**: 207-220 [PMID: 32399434 DOI: 10.1159/000504650]

28 **Makuuchi M**, Kokudo N. Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan. *World J Gastroenterol* 2006; **12**: 828-829 [PMID: 16521207 DOI: 10.3748/wjg.v12.i5.828]

29. Clinical Practice Guidelines for Hepatocellular Carcinoma - The Japan Society of Hepatology 2009 update. *Hepatol Res* 2010; **40 Suppl 1**: 2-144 [PMID: 20586808 DOI: 10.1111/j.1872-034X.2010.00650.x]

30 **Kokudo N**, Hasegawa K, Akahane M, Igaki H, Izumi N, Ichida T, Uemoto S, Kaneko S, Kawasaki S, Ku Y, Kudo M, Kubo S, Takayama T, Tateishi R, Fukuda T, Matsui O, Matsuyama Y, Murakami T, Arii S, Okazaki M, Makuuchi M. Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). *Hepatol Res* 2015; **45** [PMID: 25625806 DOI: 10.1111/hepr.12464]

31 **Kokudo N**, Takemura N, Hasegawa K, Takayama T, Kubo S, Shimada M, Nagano H, Hatano E, Izumi N, Kaneko S, Kudo M, Iijima H, Genda T, Tateishi R, Torimura T, Igaki H, Kobayashi S, Sakurai H, Murakami T, Watadani T, Matsuyama Y. Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. *Hepatol Res* 2019; **49**: 1109-1113 [PMID: 31336394 DOI: 10.1111/hepr.13411]

32 **Kanda Y**. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. *Bone Marrow Transplant* 2013; **48**: 452-458 [PMID: 23208313 DOI: 10.1038/bmt.2012.244]

33 **Chen MS**, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, Lin XJ, Lau WY. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. *Ann Surg* 2006; **243**: 321-328 [PMID: 16495695 DOI: 10.1097/01.sla.0000201480.65519.b8]

34 **Huang J**, Yan L, Cheng Z, Wu H, Du L, Wang J, Xu Y, Zeng Y. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. *Ann Surg* 2010; **252**: 903-912 [PMID: 21107100 DOI: 10.1097/SLA.0b013e3181efc656]

35 **Feng K**, Yan J, Li X, Xia F, Ma K, Wang S, Bie P, Dong J. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. *J Hepatol* 2012; **57**: 794-802 [PMID: 22634125 DOI: 10.1016/j.jhep.2012.05.007]

36 **Fang Y**, Chen W, Liang X, Li D, Lou H, Chen R, Wang K, Pan H. Comparison of long-term effectiveness and complications of radiofrequency ablation with hepatectomy for small hepatocellular carcinoma. *J Gastroenterol Hepatol* 2014; **29**: 193-200 [PMID: 24224779 DOI: 10.1111/jgh.12441]

37 **Liu H**, Wang ZG, Fu SY, Li AJ, Pan ZY, Zhou WP, Lau WY, Wu MC. Randomized clinical trial of chemoembolization plus radiofrequency ablation *vs* partial hepatectomy for hepatocellular carcinoma within the Milan criteria. *Br J Surg* 2016; **103**: 348-356 [PMID: 26780107 DOI: 10.1002/bjs.10061]

38 **Lee HW**, Lee JM, Yoon JH, Kim YJ, Park JW, Park SJ, Kim SH, Yi NJ, Suh KS. A prospective randomized study comparing radiofrequency ablation and hepatic resection for hepatocellular carcinoma. *Ann Surg Treat Res* 2018; **94**: 74-82 [PMID: 29441336 DOI: 10.4174/astr.2018.94.2.74]

39 **Izumi N,** Hasegawa K, Nishioka Y, Takayama T, Yamanaka N, Kudo M, Shimada M, Inomata M, Kaneko S, Baba H, Koike K, Omata M, Makuuchi M, Matsuyama Y, Kokudo N. A multicenter randomized controlled trial to evaluate the efficacy of surgery vs. radiofrequency ablation for small hepatocellular carcinoma (SURF trial). *Journal of Clinical Oncology* 2019; **37**: 4002-4002 [DOI: 10.1200/JCO.2019.37.15\_suppl.4002]

40 **Kudo M,** Hasegawa K, Kawaguchi Y, Takayama T, Izumi N, Yamanaka N, Shimada M, Inomata M, Kaneko S, Baba H, Koike K, Omata M, Makuuchi M, Matsuyama Y, Kokudo N. A multicenter randomized controlled trial to evaluate the efficacy of surgery *vs* radiofrequency ablation for small hepatocellular carcinoma (SURF trial): Analysis of overall survival. *Journal of Clinical Oncology* 2021; **39**: 4093-4093 [DOI: 10.1200/JCO.2021.39.15\_suppl.4093]

41 **Lencioni R**, Cioni D, Crocetti L, Franchini C, Pina CD, Lera J, Bartolozzi C. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. *Radiology* 2005; **234**: 961-967 [PMID: 15665226 DOI: 10.1148/radiol.2343040350]

42 **Choi D**, Lim HK, Rhim H, Kim YS, Lee WJ, Paik SW, Koh KC, Lee JH, Choi MS, Yoo BC. Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series. *Eur Radiol* 2007; **17**: 684-692 [PMID: 17093964 DOI: 10.1007/s00330-006-0461-5]

43 **Lee MW**, Kang D, Lim HK, Cho J, Sinn DH, Kang TW, Song KD, Rhim H, Cha DI, Lu DSK. Updated 10-year outcomes of percutaneous radiofrequency ablation as first-line therapy for single hepatocellular carcinoma <  3 cm: emphasis on association of local tumor progression and overall survival. *Eur Radiol* 2020; **30**: 2391-2400 [PMID: 31900708 DOI: 10.1007/s00330-019-06575-0]

44 **Rosenberg I**, Cherayil BJ, Isselbacher KJ, Pillai S. Mac-2-binding glycoproteins. Putative ligands for a cytosolic beta-galactoside lectin. *J Biol Chem* 1991; **266**: 18731-18736 [PMID: 1917996]

45 **Grassadonia A**, Tinari N, Iurisci I, Piccolo E, Cumashi A, Innominato P, D'Egidio M, Natoli C, Piantelli M, Iacobelli S. 90K (Mac-2 BP) and galectins in tumor progression and metastasis. *Glycoconj J* 2002; **19**: 551-556 [PMID: 14758079 DOI: 10.1023/B:GLYC.0000014085.00706.d4]

46 **Kamada Y**, Ono M, Hyogo H, Fujii H, Sumida Y, Yamada M, Mori K, Tanaka S, Maekawa T, Ebisutani Y, Yamamoto A, Takamatsu S, Yoneda M, Kawada N, Chayama K, Saibara T, Takehara T, Miyoshi E; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG‐NAFLD). Use of Mac-2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis. *Hepatol Commun* 2017; **1**: 780-791 [PMID: 29404494 DOI: 10.1002/hep4.1080]

47 **Bedossa P**, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. *Hepatology* 1996; **24**: 289-293 [PMID: 8690394 DOI: 10.1002/hep.510240201]

48 **Shirabe K**, Bekki Y, Gantumur D, Araki K, Ishii N, Kuno A, Narimatsu H, Mizokami M. Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis. *J Gastroenterol* 2018; **53**: 819-826 [PMID: 29318378 DOI: 10.1007/s00535-017-1425-z]

49 **Sasaki R**, Yamasaki K, Abiru S, Komori A, Nagaoka S, Saeki A, Hashimoto S, Bekki S, Kugiyama Y, Kuno A, Korenaga M, Togayachi A, Ocho M, Mizokami M, Narimatsu H, Ichikawa T, Nakao K, Yatsuhashi H. Serum Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein Values Predict the Development of Hepatocellular Carcinoma among Patients with Chronic Hepatitis C after Sustained Virological Response. *PLoS One* 2015; **10**: e0129053 [PMID: 26070204 DOI: 10.1371/journal.pone.0129053]

50 **Tamaki N**, Kurosaki M, Kuno A, Korenaga M, Togayachi A, Gotoh M, Nakakuki N, Takada H, Matsuda S, Hattori N, Yasui Y, Suzuki S, Hosokawa T, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Mizokami M, Narimatsu H, Izumi N. Wisteria floribunda agglutinin positive human Mac-2-binding protein as a predictor of hepatocellular carcinoma development in chronic hepatitis C patients. *Hepatol Res* 2015; **45**: E82-E88 [PMID: 25559682 DOI: 10.1111/hepr.12466]

51 **Kawaguchi K**, Honda M, Ohta H, Terashima T, Shimakami T, Arai K, Yamashita T, Sakai Y, Yamashita T, Mizukoshi E, Komura T, Unoura M, Kaneko S. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B. *J Gastroenterol* 2018; **53**: 740-751 [PMID: 28849280 DOI: 10.1007/s00535-017-1386-2]

52 **Liu J**, Hu HH, Lee MH, Korenaga M, Jen CL, Batrla-Utermann R, Lu SN, Wang LY, Mizokami M, Chen CJ, Yang HI. Serum Levels of M2BPGi as Short-Term Predictors of Hepatocellular Carcinoma in Untreated Chronic Hepatitis B Patients. *Sci Rep* 2017; **7**: 14352 [PMID: 29085039 DOI: 10.1038/s41598-017-14747-5]

53 **Ichikawa Y**, Joshita S, Umemura T, Shobugawa Y, Usami Y, Shibata S, Yamazaki T, Fujimori N, Komatsu M, Matsumoto A, Tanaka E. Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein may predict liver fibrosis and progression to hepatocellular carcinoma in patients with chronic hepatitis B virus infection. *Hepatol Res* 2017; **47**: 226-233 [PMID: 27029022 DOI: 10.1111/hepr.12712]

54 **Cheung KS**, Seto WK, Wong DK, Mak LY, Lai CL, Yuen MF. Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts liver cancer development in chronic hepatitis B patients under antiviral treatment. *Oncotarget* 2017; **8**: 47507-47517 [PMID: 28537900 DOI: 10.18632/oncotarget.17670]

55 **Heo JY**, Kim SU, Kim BK, Park JY, Kim DY, Ahn SH, Park YN, Ahn SS, Han KH, Kim HS. Use of Wisteria Floribunda Agglutinin-Positive Human Mac-2 Binding Protein in Assessing Risk of Hepatocellular Carcinoma Due to Hepatitis B Virus. *Medicine (Baltimore)* 2016; **95**: e3328 [PMID: 27057911 DOI: 10.1097/MD.0000000000003328]

56 **Yasui Y**, Kurosaki M, Komiyama Y, Takada H, Tamaki N, Watakabe K, Okada M, Wang W, Shimizu T, Kubota Y, Higuchi M, Takaura K, Tsuchiya K, Nakanishi H, Takahashi Y, Itakura J, Enomoto N, Izumi N. Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts early occurrence of hepatocellular carcinoma after sustained virologic response by direct-acting antivirals for hepatitis C virus. *Hepatol Res* 2018; **48**: 1131-1139 [PMID: 30030872 DOI: 10.1111/hepr.13233]

57 **Sato S**, Genda T, Ichida T, Amano N, Sato S, Murata A, Tsuzura H, Narita Y, Kanemitsu Y, Hirano K, Shimada Y, Iijima K, Wada R, Nagahara A, Watanabe S. Prediction of Hepatocellular Carcinoma Development after Hepatitis C Virus Eradication Using Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein. *Int J Mol Sci* 2016; **17** [PMID: 27999409 DOI: 10.3390/ijms17122143]

58 **Fujiyoshi M**, Kuno A, Gotoh M, Fukai M, Yokoo H, Kamachi H, Kamiyama T, Korenaga M, Mizokami M, Narimatsu H, Taketomi A; Hepatitis Glyco-biomarker Study Group. Clinicopathological characteristics and diagnostic performance of Wisteria floribunda agglutinin positive Mac-2-binding protein as a preoperative serum marker of liver fibrosis in hepatocellular carcinoma. *J Gastroenterol* 2015; **50**: 1134-1144 [PMID: 25773774 DOI: 10.1007/s00535-015-1063-2]

59 **Tak KY**, Jang B, Lee SK, Nam HC, Sung PS, Bae SH, Choi JY, Yoon SK, Jang JW. Use of M2BPGi in HCC patients with TACE. *J Gastroenterol Hepatol* 2021; **36**: 2917-2924 [PMID: 34031909 DOI: 10.1111/jgh.15553]

60 **Morio K**, Imamura M, Daijo K, Teraoka Y, Honda F, Nakamura Y, Kobayashi T, Nakahara T, Nagaoki Y, Kawaoka T, Tsuge M, Hiramatsu A, Kawakami Y, Aikata H, Nelson Hayes C, Tsugawa K, Yokozaki M, Chayama K. Wisteria floribunda agglutinin positive Mac-2-binding protein level increases in patients with acute liver injury. *J Gastroenterol* 2017; **52**: 1252-1257 [PMID: 28477171 DOI: 10.1007/s00535-017-1345-y]

61 **Migita K**, Horai Y, Kozuru H, Koga T, Abiru S, Yamasaki K, Komori A, Fujita Y, Asano T, Sato S, Suzuki E, Matsuoka N, Kobayashi H, Watanabe H, Naganuma A, Naeshiro N, Yoshizawa K, Ohta H, Sakai H, Shimada M, Nishimura H, Tomizawa M, Ario K, Yamashita H, Kamitsukasa H, Kohno H, Nakamura M, Furukawa H, Takahashi A, Kawakami A, Ohira H, Yastuhashi H. Serum cytokine profiles and Mac-2 binding protein glycosylation isomer (M2BPGi) level in patients with autoimmune hepatitis. *Medicine (Baltimore)* 2018; **97**: e13450 [PMID: 30557999 DOI: 10.1097/MD.0000000000013450]

62 **Hanai T**, Shiraki M, Nishimura K, Ohnishi S, Imai K, Suetsugu A, Takai K, Shimizu M, Moriwaki H. Sarcopenia impairs prognosis of patients with liver cirrhosis. *Nutrition* 2015; **31**: 193-199 [PMID: 25441595 DOI: 10.1016/j.nut.2014.07.005]

63 **Sugimoto R**, Iwasa M, Hara N, Tamai Y, Yoshikawa K, Ogura S, Tanaka H, Eguchi A, Yamamoto N, Kobayashi Y, Hasegawa H, Takei Y. Changes in liver function and body composition by direct-acting antiviral therapy for hepatitis C virus infection. *Hepatol Res* 2018; **48**: 337-344 [PMID: 29115717 DOI: 10.1111/hepr.12999]

64 **Endo K**, Sato T, Suzuki A, Yoshida Y, Kakisaka K, Miyasaka A, Takikawa Y. Sustained virologic response by direct-acting antivirals suppresses skeletal muscle loss in hepatitis C virus infection. *J Gastroenterol Hepatol* 2020; **35**: 1602-1609 [PMID: 31975438 DOI: 10.1111/jgh.14991]

**Footnotes**

**Institutional review board statement:** The study protocol was approved by the Institutional Ethics Committee of Hokkaido University (IRB no. 015-1412) and conformed to the ethical guidelines of the Declaration of Helsinki.

**Informed consent statement:** All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** There are no conflicts of interest to report.

**Data sharing statement:** No additional data are available.

**STROBE statement:** The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** February 25, 2022

**First decision:** April 8, 2022

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Japan

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Mohamed GA, Egypt; Yuan H, China **S-Editor:** Wang LL **L-Editor:** A **P-Editor:**

**Figure Legends**

**ダイアグラム

自動的に生成された説明**

**Figure 1 Patients’ flow.** HCV: hepatitis C virus; HCC: hepatocellular carcinoma; RFA: radiofrequency ablation; BCLC: Barcelona Clinic Liver Cancer; CT: computed tomography.

**グラフ, 箱ひげ図

自動的に生成された説明**

**Figure 2 The value of Mac-2 binding protein and Mac-2 binding protein glycosylation isomer in hepatitis C virus**-**positive and** -**negative patients.** A: The values of Mac-2 binding protein in hepatitis C virus (HCV)-negative and -positive groups; B: The values of Mac-2 binding protein glycosylation isomer in HCV-negative and -positive groups. The box charts for the Y-axis indicate the median as bold lines in the boxes, 25th and 75th percentiles as boxes, and 10th and 90th percentiles as lines for each edge. HCV: hepatitis C virus; M2BPGi: Mac-2 binding protein; M2BPGi: Mac-2 binding protein glycosylation isomer.

**ダイアグラム, 設計図

自動的に生成された説明**

**Figure 3 Recurrence rate according to the value of Mac-2 binding protein and Mac-2 binding protein glycosylation isomer.** The hepatocellular carcinoma recurrence rate was divided into two groups according to the value of Mac-2 binding protein (M2BP) or M2BP glycosylation isomer (M2BPGi) before radiofrequency ablation. A: Hepatitis C virus (HCV)-positive group divided by M2BP value. The gray line indicates patients with M2BP < 5385 ng/mL, and the black line indicates patients with M2BP ≥ 5385 ng/mL; B: HCV-positive group divided by M2BPGi value. The gray line indicates patients with M2BPGi < 4.94 cutoff index (COI), and the black line indicates patients with M2BPGi ≥ 4.94 COI; C: HCV-negative group divided by M2BP value. The gray line indicates patients with M2B*P <* 2745 ng/mL, and the black line indicates patients with M2BP ≥ 2745 ng/mL; D: HCV-negative group divided by M2BPGi value. The gray line indicates patients with M2BP *<* 1.86 COI, and the black line indicates patients with M2BPGi ≥ 1.86 COI. HCV: hepatitis C virus; M2BPGi: Mac-2 binding protein; M2BPGi: Mac-2 binding protein glycosylation isomer.

**ダイアグラム

自動的に生成された説明**

**Figure 4 Survival rate according to the value of Mac-2 binding protein and Mac-2 binding protein glycosylation isomer.** The liver disease-related death-free survival rate was divided into two groups according to the value of Mac-2 binding protein (M2BP) or M2BP glycosylation isomer (M2BPGi) before radiofrequency ablation. A: Hepatitis C virus (HCV)-positive patients divided by M2BP value. The gray line indicates patients with M2BP < 5385 ng/mL, and the black line indicates patients with M2BP ≥ 5385 ng/mL; B: HCV-positive patients divided by M2BPGi value. The gray line indicates patients with M2BPGi < 4.94 cutoff index (COI), and the black line indicates patients with M2BPGi ≥ 4.94 COI; C: HCV-negative patients divided by M2BP value. The gray line indicates patients with M2B*P <* 2745 ng/mL, and the black line indicates patients with M2BP ≥ 2745 ng/mL; D: HCV-negative patients divided by M2BPGi value. The gray line indicates patients with M2BPGi < 1.86 COI, and the black line indicates patients with M2BPGi ≥ 1.86 COI. HCV: hepatitis C virus; M2BPGi: Mac-2 binding protein; M2BPGi: Mac-2 binding protein glycosylation isomer.

**グラフ が含まれている画像

自動的に生成された説明**

**Figure 5 Survival rate with or without pre-sarcopenia.** The liver disease-related survival rate was divided into two groups according to the presence of pre-sarcopenia before radiofrequency ablation. A: Hepatitis C virus (HCV)-positive group; B: HCV-negative group. The gray line indicates patients without pre-sarcopenia, and the black line indicates patients with pre-sarcopenia. The numbers under each group indicate the number at risk for each group. HCV: hepatitis C virus; M2BPGi: Mac-2 binding protein; M2BPGi: Mac-2 binding protein glycosylation isomer.

**Table 1 Patient characteristics**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **HCV-positive (*n* = 83)** | **HCV-negative (*n* = 77)** | ***P*-value** |
| Sex (male/female) | 45/38 | 50/27 | 0.20 |
| Age (years1 | 70 (44-90) | 64 (41-88) | < 0.01 |
| Tumor factors |  |  |  |
| Tumor number (solitary/multiple) | 63/20 | 68/9 | 0.07 |
| Tumor size (mm)1 | 17 (8-30) | 15 (6-30) | 0.05 |
| Tumor form (only boundary/others) | 67/16 | 68/9 | 0.20 |
| Stage (LCSG)(I/II/III) | 39/38/6 | 45/27/5 | 0.35 |
| Liver function |  |  |  |
| Child-Pugh Score (5-6/7-9) | 66/17 | 66/11 | < 0.01 |
| ALBI grade (1/2-3) | 27/56 | 43/34 | 0.41 |
| Blood data |  |  |  |
| Platelet (×104/µL)1 | 10.2 (2.7-43.7) | 11.8 (3.7-36.8) | 0.04 |
| AST (U/L)1 | 56 (18-139) | 39 (16-100) | < 0.01 |
| ALT (U/L)1 | 49 (12-155) | 30 (9-87) | < 0.01 |
| FIB-4 index1 | 5.90 (0.96-37.86) | 3.61 (0.88-14.16) | < 0.01 |
| APRI1 | 2.00 (0.15-15.06) | 1.08 (0.28-4.32) | < 0.01 |
| PT (%)1 | 84.6 (48.6-125.0) | 81.3 (51.8-117.1) | 0.51 |
| Total bilirubin (mg/dL)1 | 0.9 (0.2-2.8) | 0.9 (0.4-2.7) | 0.56 |
| Albumin (g/dL)1 | 3.7 (2.2-4.7) | 4.0 (2.4-5.0) | < 0.01 |
| AFP (ng/mL)1 | 17.4 (3.0-621.6) | 6.4 (1.3-1962.9) | < 0.01 |
| DCP (mAU/mL)1 | 23 (4-1086) | 22 (7-6308) | 0.66 |
| AFP-L3 (%)1 | 5.1 (< 0.5-69.1) | < 0.5 (< 0.5-85.6) | 0.03 |
| M2BPGi (COI)1 | 4.94 (0.78-17.81) | 1.86 (0.36-10.23) | < 0.01 |
| M2BP (ng/mL)1 | 5385 (1460-22770) | 2745 (865-12150) | < 0.01 |
| SMI (cm2/m2)1 | 5.28 (2.62-11.75) | 6.51 (2.58-10.89) | < 0.01 |
| Pre-sarcopenia, *n* (%) | 21 (25.3) | 14 (18.2) | 0.34 |
| Observation period(mo)1 | 46 (6-157) | 56 (6-185) | 0.19 |

1Median (range). APRI (AST to platelet ratio index) = AST/platelet. FIB4 index = (age × AST)/(platelet × alanine aminotransferase × 0.5). HCV: hepatitis C virus; LCSG: liver cancer study group; ALBI: albumin-bilirubin; AST: aspartate aminotransferase; ALT: alanine aminotransferase; PT: prothrombin time; AFP: alfa-fetoprotein; DCP: des-γ-carboxyprothrombin; M2BPGi: Mac-2 binding protein glycosylation isomer; M2BP: Mac-2 binding protein; SMI: skeletal muscle mass index.

**Table 2 Factors contributing to survival in hepatitis C virus-positive patients**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Subject** | **Univariate** | **Multivariate** | | |
| ***P*-value** | **HR** | **95% CI** | ***P*-value** |
| Age (< 70/≥ 70 years) | 0.08 | 1.92 | 0.94-3.94 | 0.074 |
| Sex (Female/Male) | 0.13 |  |  |  |
| ALBI grade (1/2,3) | 0.06 | 1.81 | 0.84-3.90 | 0.129 |
| Child-Pugh Score (5-6/7-15) | 0.15 |  |  |  |
| Stage (LCSG) (I/II+III) | 0.47 |  |  |  |
| Tumor number (solitary/multiple) | 0.97 |  |  |  |
| Tumor form (only boundary/others) | 0.43 |  |  |  |
| Tumor size (< 20 mm/≥ 20 mm) | 0.54 |  |  |  |
| AFP (< 17.2/≥ 17.2 ng/mL) | 0.12 |  |  |  |
| DCP (< 23/≥ 23 mAU/mL) | < 0.01 | 2.54 | 1.23-5.23 | 0.012 |
| AFP-L3 (< 10/≥ 10%) | 0.02 | 1.72 | 0.80-3.71 | 0.167 |
| M2BPGi (< 4.94/≥ 4.94 COI) | 0.26 |  |  |  |
| M2BP (< 5385/≥ 5385 ng/mL) | 0.24 |  |  |  |
| APRI (< 2.0/≥ 2.0) | 0.58 |  |  |  |
| FIB-4 index (< 4.5/≥ 4.5) | 0.31 |  |  |  |
| Pre-sarcopenia (No/Yes) | 0.28 |  |  |  |

APRI (AST to platelet ratio index) = AST/platelet. FIB4 index = (age × AST)/(platelet × alanine aminotransferase × 0.5). HR: hazard ratio; CI: confidence interval; ALBI: albumin-bilirubin; LCSG: liver cancer study group; AST: aspartate aminotransferase; ALT: alanine aminotransferase; PT: prothrombin time; AFP: alfa-fetoprotein; DCP: des-γ-carboxyprothrombin; M2BPGi: Mac-2 binding protein glycosylation isomer; COI: cutoff index; M2BP: Mac-2 binding protein.

**Table 3 Factors contributing to survival in hepatitis C virus-negative patients**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Subject** | **Univariate** | **Multivariate** | | |
| ***P*-value** | **HR** | **95% CI** | ***P*-value** |
| Age (< 65/≥ 65) | 0.03 | - |  |  |
| Sex (Female/Male) | 0.88 |  |  |  |
| ALBI grade (1/2,3) | < 0.01 | 2.41 | 0.81-7.12 | 0.115 |
| Child-Pugh Score (5-6/7-15) | < 0.01 | - |  |  |
| Stage (LCSG) (I/II+III) | 0.91 |  |  |  |
| Tumor number (solitary/multiple) | 0.54 |  |  |  |
| Tumor form (boundary/others) | 0.11 |  |  |  |
| Tumor size (< 20 mm/≥ 20 mm) | 0.74 |  |  |  |
| AFP (< 6.4/≥ 6.4 ng/mL) | 0.64 |  |  |  |
| DCP (< 22/≥ 22 mAU/mL) | 0.23 |  |  |  |
| AFP-L3 (< 10/≥ 10%) | 0.29 |  |  |  |
| M2BPGi (< 1.86/≥ 1.86 COI) | < 0.01 | 4.89 | 1.97-12.18 | < 0.001 |
| M2BP (< 2745/≥ 2745 ng/mL) | 0.92 |  |  |  |
| APRI (< 1.5/≥ 1.5) | 0.04 | - |  |  |
| FIB-4 index (< 3.6/≥ 3.6) | < 0.01 | 1.86 | 0.63-5.44 | 0.257 |
| Pre-sarcopenia (no/yes) | 0.04 | 3.34 | 1.19-9.37 | 0.022 |

APRI (AST to platelet ratio index) = AST/platelet. FIB4 index = (age × AST)/(platelet × alanine aminotransferase × 0.5). HR: hazard ratio; CI: confidence interval; ALBI: albumin-bilirubin; LCSG: liver cancer study group; AST: aspartate aminotransferase; ALT: alanine aminotransferase; PT: prothrombin time; AFP: alfa-fetoprotein; DCP: des-γ-carboxyprothrombin; M2BPGi: Mac-2 binding protein glycosylation isomer; COI: cutoff index; M2BP: Mac-2 binding protein.